Impaired functional responses in follicular lymphoma CD8⁺TIM-3⁺ T lymphocytes following TCR engagement

References

• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-23; PMID:15494430; http://dx.doi.org/10.1182/blood-2004-08-3175
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-32; PMID:16123223; http://dx.doi.org/10.1182/blood-2005-01-0016
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, Haioun C, Brice P, Mahé B, Bouabdallah R et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112:4824-31; PMID:18799723; http://dx.doi.org/10.1182/blood-2008-04-153189
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvadó MT, Lopez C, Jaén J, Bosch R, Pons LE. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24:5350-7; PMID:17135637; http://dx.doi.org/10.1200/JCO.2006.06.4766
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-69; PMID:15548776; http://dx.doi.org/10.1056/NEJMoa041869
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, Christensson B, Sander B, Kimby E. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1–positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16:637-50; PMID:20068089; http://dx.doi.org/10.1158/1078-0432.CCR-09-2487
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093-102; PMID:19946335; http://dx.doi.org/10.1038/onc.2009.416
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13:388-97; PMID:17255259; http://dx.doi.org/10.1158/1078-0432.CCR-06-1734
   PubMed Web of Science ®Google Scholar
• Laurent C, Müller S, Do C, Al-Saati T, Allart S, Larocca LM, Hohaus S, Duchez S, Quillet-Mary A, Laurent G et al. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood 2011; 118:5371-9; PMID:21856865; http://dx.doi.org/10.1182/blood-2011-04-345777
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE, Ansell SM. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012; 122:1271-82; PMID:22426209; http://dx.doi.org/10.1172/JCI59806
   PubMed Web of Science ®Google Scholar
• Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012; 7:e30676; PMID:22363469; http://dx.doi.org/10.1371/journal.pone.0030676
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207:2175-86; PMID:20819923; http://dx.doi.org/10.1084/jem.20100637
   PubMed Web of Science ®Google Scholar
• Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56:1342-51; PMID:22505239; http://dx.doi.org/10.1002/hep.25777
   PubMed Web of Science ®Google Scholar
• Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 2012; 24:213-6; PMID:22226204; http://dx.doi.org/10.1016/j.coi.2011.12.005
   PubMed Web of Science ®Google Scholar
• Liu X, Gibbons RM, Harrington SM, Krco CJ, Markovic SN, Kwon ED, Dong H. Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology 2013; 2:e23972; PMID:23894697; http://dx.doi.org/10.4161/onci.23972
   PubMed Web of Science ®Google Scholar
• Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol 2015; 45(7):1892-905; PMID:26018646; http://dx.doi.org/10.1002/eji.201344413
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27:670-84; PMID:17950003; http://dx.doi.org/10.1016/j.immuni.2007.09.006
   PubMed Web of Science ®Google Scholar
• Crawford A, Wherry EJ. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol 2009; 21:179-86; PMID:19264470; http://dx.doi.org/10.1016/j.coi.2009.01.010
   PubMed Web of Science ®Google Scholar
• Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, Umetsu DT. The costimulatory role of TIM molecules. Immunol Rev 2009; 229:259-70; PMID:19426227; http://dx.doi.org/10.1111/j.1600-065X.2009.00772.x
   PubMed Web of Science ®Google Scholar
• Clayton KL, Haaland MS, Douglas-Vail MB, Mujib S, Chew GM, Ndhlovu LC, Ostrowski MA. T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J Immunol 2014; 192:782-91; PMID:24337741; http://dx.doi.org/10.4049/jimmunol.1302663
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, Lister TA, Lee AM, Calaminici M, Gribben JG. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114:4713-20; PMID:19786615; http://dx.doi.org/10.1182/blood-2009-04-217687
   PubMed Web of Science ®Google Scholar
• Kabanova A, Sanseviero F, Veronica C, Gamberucci A, Gozzetti A, Campoccia G, Bocchia M, Baldari CT. Human Cytotoxic T Lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release. Cell Rep 2016; 15:9-18; PMID:27052167; http://dx.doi.org/10.1016/j.celrep.2016.02.084
   PubMed Web of Science ®Google Scholar
• Valitutti S, Müller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996; 183:1917-21; PMID:8666949; http://dx.doi.org/10.1084/jem.183.4.1917
   PubMed Web of Science ®Google Scholar
• Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205:2763-79; PMID:19001139; http://dx.doi.org/10.1084/jem.20081398
   PubMed Web of Science ®Google Scholar
• Ju Y, Hou N, Zhang XN, Zhao D, Liu Y, Wang JJ, Luan F, Shi W, Zhu FL, Sun WS et al. Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol 2009; 6:35-43; PMID:19254478; http://dx.doi.org/10.1038/cmi.2009.5
   PubMed Web of Science ®Google Scholar
• Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, Castelblanco N, Kuchroo V, Gretch DR, Rosen HR. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 2009; 83:9122-30; PMID:19587053; http://dx.doi.org/10.1128/JVI.00639-09
   PubMed Web of Science ®Google Scholar
• Sehrawat S, Reddy PB, Rajasagi N, Suryawanshi A, Hirashima M, Rouse BT. Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog 2010; 6:e1000882; PMID:20463811; http://dx.doi.org/10.1371/journal.ppat.1000882
   PubMed Web of Science ®Google Scholar
• Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, Freeman GJ, Kuchroo VK, Ahmed R. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010; 107:14733-8; PMID:20679213; http://dx.doi.org/10.1073/pnas.1009731107
   PubMed Web of Science ®Google Scholar
• Robertson LK, Mireau LR, Ostergaard HL. A role for phosphatidylinositol 3-kinase in TCR-stimulated ERK activation leading to paxillin phosphorylation and CTL degranulation. J Immunol 2005; 175:8138-45; PMID:16339552; http://dx.doi.org/10.4049/jimmunol.175.12.8138
   PubMed Web of Science ®Google Scholar
• Metz PJ, Arsenio J, Kakaradov B, Kim SH, Remedios KA, Oakley K, Akimoto K, Ohno S, Yeo GW, Chang JT. Regulation of asymmetric division and CD8+ T lymphocyte fate specification by protein kinase Cζ and protein kinase Cλ/ι. J Immunol 2015; 194:2249-59; PMID:25617472; http://dx.doi.org/10.4049/jimmunol.1401652
   PubMed Web of Science ®Google Scholar
• Dumont FJ, Staruch MJ, Fischer P, DaSilva C, Camacho R. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol 1998; 160:2579-89; PMID:9510155
   PubMed Web of Science ®Google Scholar
• Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, Brousset P, Bidaut A, Ycart B, Fournié JJ et al. Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology 2015 Apr 2; 4(8):e1026530; PMID:26405585; PMCID:PMC4570141; http://dx.doi.org/10.1080/2162402X.2015.1026530
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2014; 65:185-202; PMID:24188664; http://dx.doi.org/10.1146/annurev-med-092012-112807
   PubMed Web of Science ®Google Scholar
• Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15:69-77; PMID:24332512; http://dx.doi.org/10.1016/S1470-2045(13)70551-5
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207:2187-94; PMID:20819927; http://dx.doi.org/10.1084/jem.20100643
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 2016; 7:10501; PMID:26883990; http://dx.doi.org/10.1038/ncomms10501
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-Targeted Antitumor Immunotherapy. Cancer Res 2011; 71:6567-71; PMID:22009533; http://dx.doi.org/10.1158/0008-5472.CAN-11-1487
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition. In: IARC Presse L, ed., 2008:439
   Google Scholar
• Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17:1244; PMID:10561185
   PubMed Web of Science ®Google Scholar
• Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78; PMID:14580882; http://dx.doi.org/10.1016/S0022-1759(03)00265-5
   PubMed Web of Science ®Google Scholar
• Irish JM, Czerwinski DK, Nolan GP, Levy R. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006; 177:1581-9; PMID:16849466; http://dx.doi.org/10.4049/jimmunol.177.3.1581
   PubMed Web of Science ®Google Scholar
• Bertrand F, Müller S, Roh KH, Laurent C, Dupré L, Valitutti S. An initial and rapid step of lytic granule secretion precedes microtubule organizing center polarization at the cytotoxic T lymphocyte/target cell synapse. Proc Natl Acad Sci U S A 2013; 110:6073-8; PMID:23536289; http://dx.doi.org/10.1073/pnas.1218640110
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545-50; PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Laurent C, Guérin M, Frenois FX, Thuries V, Jalabert L, Brousset P, Valmary-Degano S. Whole-slide imaging is a robust alternative to traditional fluorescent microscopy for fluorescence in situ hybridization imaging using break-apart DNA probes. Hum Pathol 2013; 44:1544-55; PMID:23517924; http://dx.doi.org/10.1016/j.humpath.2012.12.009
   PubMed Web of Science ®Google Scholar